Takeda Pharmaceutical Company Limited
In the published model solve dated 2026-Q2, anchored at $16.72, Takeda Pharmaceutical Company Limited (TAK) is priced for +17.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• Takeda trades at roughly 0.57 times book value into a twelve-month window with three planned launches, oveporexton (narcolepsy, filed in the U.S., Japan, and China), rusfertide (polycythemia vera), and zasocitinib (psoriasis), while the price embeds only about 5% annual operating growth [Source: Takeda FY2025 results, May 2026]. • The biggest risk is the levered transition: about $22.0 billion of net debt at roughly 2 times interest coverage, FY2026 core operating profit guided down 5% to 8%
Is TAK overvalued? See what's priced in →
356 institutional managers reported holding TAK in 13F filings for the quarter ended 2026-03-31. Together they hold about 6% of the company; the top 10 hold 4%. 52 opened new positions that quarter. Held by FMR (Fidelity), Morgan Stanley, Goldman Sachs, among others. On the short side, 5.4M shares were sold short as of the 2026-06-15 count, about 0.3% of shares outstanding (1.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TAK's share count grew 1.1% over the past five years. It pays a dividend, and has paid one every year in our records (9 and counting), raised 2 years straight. Cash returned over the past three years: $3.94B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.